AMENDMENT NO. 1 TO OPTION AND LICENSE AGREEMENTOption and License Agreement • November 8th, 2018 • Arcus Biosciences, Inc. • Pharmaceutical preparations • California
This Amendment No. 1 to the Option and License Agreement (this “Amendment”) is made and entered into effective as of September 1, 2018 (the “Amendment Effective Date”) by and between Arcus Biosciences, Inc., a company organized under the laws of State of Delaware, U.S.A., having a business address at 3928 Point Eden Way, Hayward, CA 94545, U.S.A. (“Arcus”), and TAIHO Pharmaceutical Co., Ltd., a corporation organized under the laws of Japan, having a business address at 1-27 Kandanishiki-cho, Chiyoda-ku, Tokyo 101-8444, Japan (“TAIHO”). Arcus and TAIHO are sometimes collectively referred to herein as the “Parties” and separately as a “Party.” Capitalized terms used herein but not defined herein shall have the meaning set forth in that certain Option and License Agreement made and entered into effective as of September 19, 2017, by and between Arcus and TAIHO (the “Agreement”).
ARCUS BIOSCIENCES, INC. SEVERANCE AND CHANGE IN CONTROL AGREEMENTSeverance and Change in Control Agreement • November 8th, 2018 • Arcus Biosciences, Inc. • Pharmaceutical preparations • California
This Severance and Change in Control Agreement (the “Agreement”) is made and entered into by and between _________ (“Executive”) and Arcus Biosciences, Inc., a Delaware corporation (the “Company”), effective as of the date specified in Section 1 below.
